Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 398

1.

Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.

Kim KI, Lee DE, Cho I, Yoon JH, Yoon SS, Lee HS, Oh JM.

Ann Pharmacother. 2012 Dec;46(12):1637-44. doi: 10.1345/aph.1R396. Epub 2012 Nov 20.

PMID:
23170032
2.

Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.

Schwartzberg L, Jackson J, Jain G, Balu S, Buchner D.

Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):481-8. doi: 10.1586/erp.11.47. Epub 2011 Jun 28.

PMID:
21711119
3.
5.

Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.

Celio L, Agustoni F, Testa I, Dotti K, de Braud F.

Tumori. 2012 May-Jun;98(3):279-86. doi: 10.1700/1125.12393. Review.

6.
8.

Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.

Kimura H, Yamamoto N, Shirai T, Nishida H, Hayashi K, Tanzawa Y, Takeuchi A, Igarashi K, Inatani H, Shimozaki S, Kato T, Aoki Y, Higuchi T, Tsuchiya H.

Cancer Med. 2015 Mar;4(3):333-41. doi: 10.1002/cam4.373. Epub 2014 Dec 23.

9.

Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.

Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S.

Lancet Oncol. 2009 Feb;10(2):115-24. doi: 10.1016/S1470-2045(08)70313-9. Epub 2009 Jan 8. Erratum in: Lancet Oncol. 2010 Mar;11(3)226.

PMID:
19135415
10.

The efficacy of triplet antiemetic therapy with 0.75 mg of palonosetron for chemotherapy-induced nausea and vomiting in lung cancer patients receiving highly emetogenic chemotherapy.

Miura S, Watanabe S, Sato K, Makino M, Kobayashi O, Miyao H, Iwashima A, Okajima M, Tanaka J, Tanaka H, Kagamu H, Yokoyama A, Narita I, Yoshizawa H.

Support Care Cancer. 2013 Sep;21(9):2575-81. doi: 10.1007/s00520-013-1835-2. Epub 2013 May 5.

PMID:
23644992
11.
12.

Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Longo F, Mansueto G, Lapadula V, De Sanctis R, Quadrini S, Grande R, Gori B, Altavilla A, D'Antoni I, Del Signore E, Stumbo L, De Luca C, Cimadon B, Cortesi E, Gamucci T, Di Seri M.

Support Care Cancer. 2011 Aug;19(8):1159-64. doi: 10.1007/s00520-010-0930-x. Epub 2010 Jun 16.

PMID:
20552375
13.

Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial.

Boccia R, Grunberg S, Franco-Gonzales E, Rubenstein E, Voisin D.

Support Care Cancer. 2013 May;21(5):1453-60. doi: 10.1007/s00520-012-1691-5. Epub 2013 Jan 26.

14.

Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study.

Lin SJ, Hatoum HT, Buchner D, Cox D, Balu S.

BMC Health Serv Res. 2012 Jul 23;12:215. doi: 10.1186/1472-6963-12-215.

15.
16.

Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL).

Di Renzo N, Montanini A, Mannina D, Dondi A, Muci S, Mancuso S, De Paolis MR, Plati C, Stelitano C, Patti C, Olivieri A, Liardo E, Buda G, Cantaffa R, Federico M.

Support Care Cancer. 2011 Oct;19(10):1505-10. doi: 10.1007/s00520-010-0974-y. Epub 2010 Aug 8.

17.

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.

Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A, Macciocchi A, Grunberg S; 99-04 Palonosetron Study Group.

Cancer. 2003 Dec 1;98(11):2473-82.

18.

Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.

Hajdenberg J, Grote T, Yee L, Arevalo-Araujo R, Latimer LA.

J Support Oncol. 2006 Oct;4(9):467-71.

PMID:
17080735
19.

Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients.

Dong X, Huang J, Cao R, Liu L.

Med Oncol. 2011 Dec;28(4):1425-9. doi: 10.1007/s12032-010-9608-y. Epub 2010 Jul 3.

PMID:
20602263
20.

Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.

Navari RM.

J Support Oncol. 2003 Jul-Aug;1(2):89-103. Review.

PMID:
15352652
Items per page

Supplemental Content

Write to the Help Desk